Lux Capital raises $350M to expand its startup portfolio

Lux Capital, a New York venture investor, put together a $350 million fourth fund, cash that will help bankroll startups in energy, technology and biotech. The firm, which also has an outpost in Menlo Park, CA, boasts a life sciences portfolio that includes Cerulean Pharma ($CERU), Kala Pharmaceuticals, Visterra and Genocea Biosciences ($GNCA). More

Suggested Articles

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.

Grid Therapeutics is planning to start trials of its lead cancer immunotherapy GT103 next year after raising $5 million in second-round financing.

The IPO comes as the Flagship startup prepares to test its lead inflammatory disease and anticancer microbial strains in humans.